Feature | September 03, 2008| Venkat Rajan, medical research analyst, Frost & Sullivan

An Introduction to Stents: Coronary, Carotid, Peripheral

The Drug-Eluting Revolution and the Evolution of a Dynamic Market

This comparison chart features three categories of stents: coronary, carotid and peripheral. We gratefully acknowledge the assistance of Mark Paquin, contributing editor and editorial advisory board member, in drafting specification questions, as well as the manufacturers whose contributions of specs have made this chart a useful tool for physicians.

The article by Frost & Sullivan market analyst Venkat Rajan is a discussion of the DES market and the author's perspectives and forecasts.

The launch of any novel therapy often undergoes a hype cycle in which there is a great deal of interest from market innovators followed by a rise of backlash from specialists who prefer the alternate, more common methods, and ultimately a reconciliation from the two viewpoints. In the case of drug-eluting stents (DES), which initially experienced tremendous growth in the medical device industry, clinical use has slowed recently due to questions concerning the safety of DES. However, manufacturers are confident the next generation of DES will overcome any serious safety issues.

With their hybrid pharmacological coatings and intricate wire mesh design, DES are an elaborate fusion of high-level polymer technologies and specialized device design. These devices can cost several thousands of dollars apiece and it's not uncommon for two or three stents to be used in a single interventional coronary procedure.

While the introduction of most new devices requires a gradual shift from more established procedures, the inherent familiarity specialists had with bare metal stents, coupled with a clinical preference for minimally invasive procedures, accelerated the product growth cycle of DES.

Increasing market maturity and the arrival of several new market entrants over the next few years creates an environment of anticipation among participants and clinicians alike, all eagerly watching for the next major leaps in coronary care.

Sizing up the Competition

Until now the market has been a fiercely contested battle between two medical device juggernauts, both employing strong marketing campaigns effusing the diversity of their product line, ease of implantation or clinical superiority. The next several years will see new product launches from other competitors such as Medtronic, Abbott Vascular and, long term, even a number of niche manufacturers such as Connor Medsystems.
Even market participants Boston Scientific with its TAXUS Liberte and Cordis/J&J with its Cypher Select are developing second generations of their popular devices. Both are expected to improve ease of delivery, implantation and safety.

New market entry and competition are expected to ramp up marketing and increase pricing pressures. It will take three to four years before clinicians determine if certain devices are suited best for specific circumstances.
Abbott's XIENCE V stent received FDA approval in July. It is important to both Abbott and Boston Scientific. When Boston Scientific bought the bulk of Guidant, it struck a deal with Abbott to market the Xience stent under a different name - PROMUS - while sharing profits with Abbott.

Next-Generation DES

Looking past the coated DES, where essentially a drug coating is spray-painted on the inside mesh frame, a number of manufacturers are exploring alternative approaches. One technique has been the use of drug depots - numerous reservoirs that slowly release the drug over time - located throughout a metal stent. The main advantage of such a device would be in ease of implantation.

Other improvements include new types of polymers. A novel hybrid stent material developed by Boston Scientific called platinum enriched stainless steel (PERSE), is engineered to increase radiopacity and strength, while remaining extremely flexible. The new material is used in Boston Scientific's new PROMUS Element and TAXUS Element DES platforms.

Innovative applications are on the horizon for solving some of the biggest industry issues. For instance, Xtent Technologies is developing a methodology for determining stent length insitu, eliminating the need for multiple overlapping devices at risk for thrombosis or stent migration. Clinicians would then be able to deploy stents of the exact size depending on the requirements of that specific occlusion site. Also, polymer technology has advanced to a stage at which completely bioabsorbable devices will soon be plausible.

Related Content

News | Venous Therapies| September 12, 2016
Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow...
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral| August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
Abbott, Absorb bioresorbable stent, University Hospitals Case Medical Center, first Midwest implant
News | Stents Bioresorbable| July 11, 2016
University Hospitals Case Medical Center, Cleveland, is among the first in the country – and the first in Ohio — to...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, dissolving stent

The Abbott Absorb is the first bioresorbable stent to be cleared for use in the United States. 

Technology | Stents Bioresorbable| July 05, 2016 | Dave Fornell
July 5, 2016 — The U.S.
News | Stents Bioresorbable| June 06, 2016
Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel Aptitude 120-...
Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent
News | Stents Drug Eluting| June 03, 2016
Biotronik announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Resolute...
Overlay Init